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Abstract
Background: Indirect comparisons of competing treatments by network meta-analysis (NMA) are increasingly in use.
Reporting bias has received little attention in this context. We aimed to assess the impact of such bias in NMAs.
Methods: We used data from 74 FDA-registered placebo-controlled trials of 12 antidepressants and their 51 matching
publications. For each dataset, NMA was used to estimate the effect sizes for 66 possible pair-wise comparisons of these
drugs, the probabilities of being the best drug and ranking the drugs. To assess the impact of reporting bias, we compared
the NMA results for the 51 published trials and those for the 74 FDA-registered trials. To assess how reporting bias affecting
only one drug may affect the ranking of all drugs, we performed 12 different NMAs for hypothetical analysis. For each of
these NMAs, we used published data for one drug and FDA data for the 11 other drugs.
Findings: Pair-wise effect sizes for drugs derived from the NMA of published data and those from the NMA of FDA data
differed in absolute value by at least 100% in 30 of 66 pair-wise comparisons (45%). Depending on the dataset used, the top
3 agents differed, in composition and order. When reporting bias hypothetically affected only one drug, the affected drug
ranked first in 5 of the 12 NMAs but second (n=2), fourth (n=1) or eighth (n=2) in the NMA of the complete FDA network.
Conclusions: In this particular network, reporting bias biased NMA-based estimates of treatments efficacy and modified
ranking. The reporting bias effect in NMAs may differ from that in classical meta-analyses in that reporting bias affecting
only one drug may affect the ranking of all drugs.
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Introduction
Comparative effectiveness research (CER) programs have
emerged as having major potential to achieve changes in health
outcomes. CER is defined as ‘‘the generation and synthesis of
evidence that compares the benefits and harms of alternative
methods to prevent, diagnose, treat, and monitor a clinical
condition’’ [1,2]. Frequently, the many existing therapeutic
approaches for a given condition have never been compared in
head-to-head randomized controlled trials [3–6]. In contrast to
usual meta-analyses, which assess whether one specific interven-
tion is effective, adjusted indirect comparisons based on network
meta-analyses (NMAs) may better answer the question posed by all
healthcare professionals: What is the best intervention among the
different existing interventions for a specific condition?
In this framework, intervention A is compared with a
comparator C, then intervention B with C, and adjusted indirect
comparison is then presumed to allow A to be compared with B
despite the lack of any head-to-head randomized trial of A vs. B.
An NMA, or mixed-treatment comparison meta-analysis, allows
for the simultaneous analysis of multiple competing interventions
by pooling direct and indirect comparisons [7,8]. The benefit is in
estimating effects sizes for all possible pair-wise comparisons of
interventions and rank-ordering them. The last few years has seen
a considerable increase in the use of indirect-comparison meta-
analyses to evaluate a wide range of healthcare interventions
[9,10]. Such methods may have a great potential for CER [11,12],
but prior to their larger dissemination, a thorough assessment of
their limits is needed.
Reporting bias is a major threat to the validity of results of
conventional systematic reviews or meta-analyses [13–17]. Re-
porting bias encompasses various types of bias, such as publication
bias, when an entire study remains unreported, and selective
analysis reporting bias, when results from specific statistical
analyses are reported selectively, both depending on the
magnitude and direction of findings [17]. Several studies have
shown that the Food and Drug Administration (FDA) repository
provides interesting opportunities for studying reporting biases
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35219[18–20]. Such biases have received little attention in the context of
NMA. We aimed to assess the impact of reporting bias on the
results of NMA.
Methods
We used datasets created from FDA reviews of antidepressants
trials and from their matching publications. For each dataset,
NMA was used to estimate all pair-wise comparisons of these
drugs. The bodies of evidence differed because entire trials
remained unpublished depending on the nature of the results.
Moreover, in some journal articles, specific analyses were reported
selectively and effect sizes differed from that of FDA reviews. By
comparing the NMA results for published trials to those for FDA-
registered trials, we assessed the impact of reporting bias as a
whole. As a proxy for the impact of publication bias only, we
compared NMA results for published trials with effect sizes from
FDA reviews to those for FDA-registered trials. As a proxy for the
impact of selective analysis reporting bias only, we compared
NMA results for published trials (with their published effect sizes)
to those for published trials with effect sizes extracted from FDA
reviews.
FDA and published datasets
The datasets we used were described and published previously
by Turner et al. (Table C of the appendix [19]). Briefly, they
identified all randomized placebo-controlled trials of 12 antide-
pressant drugs approved by the FDA and then publications
matching these trials by searching literature databases and
contacting trial sponsors. From the FDA database, the authors
identified 74 trials involving 12,564 patients comparing antide-
pressant drugs to placebo, among which results for 23 trials
involving 2,903 patients were unpublished. They extracted the
effect size values from journal articles for the 51 trials with
published results and the effect size values from FDA reviews for
the 74 FDA-registered trials. Data from journals and FDA reviews
were independently and double extracted, with any discrepancies
resolved by consensus.
The outcome was the change from baseline to follow-up in
depression score. Because depression was rated by the Hamilton
Depression Rating Scale or the Montgomery-A ˚sberg Depression
Rating scale, the effect size was a standardized mean difference
(SMD) (ie, the difference in mean pre–post change between the
antidepressant and placebo groups divided by a pooled SD within
groups).
Network meta-analysis
We performed NMAs using a Bayesian approach with a
hierarchical random effects model [7,21–23]. The model allowed
for estimating effect sizes for all 66 possible pair-wise comparisons
of the 12 antidepressant agents (12611/2, ie, 66 SMDs for any
pair of drugs). For each pair-wise comparison of drugs, we
estimated posterior median effect sizes and associated Bayesian
95% credible intervals. For details regarding the model, see
Supporting Information, Text S1. A particular advantage of the
Bayesian framework is the possibility of making explicit probability
statements about the efficacy of treatments. We computed the
probability that each antidepressant agent was the best [24]. The
ranking of the competing drugs was assessed with the median of
the posterior distribution for the rank of each drug. As well, we
arbitrarily directed each comparison (ie, agent A vs. B or B vs. A)
so that the corresponding effect size estimated by the NMA of the
74 FDA-registered trials was positive.
Statistical significance was achieved at the 5% level when the
95% posterior credibility interval did not include 0. Analysis
involved use of WinBUGS v1.4.3 (Imperial College and MRC,
London, UK) to estimate all Bayesian models and R v2.11.1 (R
Development Core Team, Vienna, Austria) to summarize
inferences and convergence.
Impact of reporting bias
To assess the impact of reporting bias, we compared the NMA
results for the 74 FDA-registered trials with effect size values
extracted from FDA reviews, considered the reference estimates,
to those for the 51 published trials with effect size values extracted
from published reports.
First, we drew a scatter plot of the 66 pair-wise effect sizes
derived from one NMA against the other. According to Cohen’s
standard rules of thumb, we considered whether the magnitude of
the pair-wise effect sizes was small (,0.2) or moderate (0.2–0.5) to
assess approximate clinical significance [25]. Second, we comput-
ed 66 relative differences between pair-wise effect sizes from both
NMAs as SMDpublished {SMDFDA  
SMDFDA    . Third, we
summarized the number of times the effect sizes from the NMAs
of the 51 published trials and the 74 FDA-registered trials differed
in absolute value by at least 100% and 50%. A difference in
absolute value by at least 50% means that the pair-wise effect size
from published data is less than half, or more than one and a half,
the effect size from FDA data, which indicates substantial
differences in estimation. A difference in absolute value by at
least 100% means that the pair-wise effect size from published data
is negative (when the effect size from FDA data is positive) or is
more than twice the effect size from FDA data, which indicates
considerable differences in estimation. We also compared the
probabilities that each antidepressant agent was the best and the
rankings of drugs obtained by each NMA.
Impact of reporting bias affecting only one drug
We assessed hypothetically how reporting bias affecting only
one drug may affect the ranking of all drugs. We performed 12
NMAs successively, assuming that reporting bias affected only one
drug, each in turn. For the drug assumed to be affected by
reporting bias, we used published trials and their published effect
sizes and for the 11 other drugs we used FDA-registered trials and
effect sizes from FDA reviews. Then we compared the probability
that each antidepressant agent was the best and the rankings of
drugs from each of these 12 NMAs to those derived from the
NMA of the 74 FDA-registered trials.
Impact of publication bias and selective analysis
reporting bias
In an exploratory analysis, we aimed to separate the impact of
different sources of reporting bias. Selective analysis reporting bias
can have an influential effect, and relatively few negative trials
have to be converted to positive trials to achieve a bias similar to
that observed if 10 times more negative trials were unpublished
[26]. The statistical analysis reported in journal articles could differ
from that of FDA reviews, which follows the pre-specified methods
(FDA reviewers revisit the original protocol submitted before a
trial was conducted and FDA statistical reviewers reanalyze raw
data from the sponsor [27]). The discrepancies could result from
deviations from the intention-to-treat principle, variations in
methods for handling drop-outs, analysis of separate multicenter
trials as one, presentation of data from single sites within
multicenter trials or baseline differences not accounted for [19].
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NMA results for the 51 published trials with effect sizes extracted
from FDA reviews to those for the 74 FDA-registered trials. We
assumed the differences would be attributable to publication bias
only (by construction, selective analysis reporting bias is no longer
operating). Then we assessed the impact of selective analysis
reporting bias by comparing the NMA results for the 51 published
trials with their published effect sizes to those for the 51 published
trials with effect sizes extracted from FDA reviews. We assumed
the differences would be attributable to selective analysis reporting
bias only (by construction, publication bias is no longer operating).
Results
Figure 1 shows the 2 radiating star networks, with the placebo in
their centers, for the 74 FDA-registered trials and 51 published
trials. The proportion of trials with unpublished results varied
substantially across antidepressant agents, from 0% for fluoxetine
and paroxetine CR to 60% and 67% for sertraline and bupropion.
Separate meta-analyses of the FDA data showed decreased
efficacy for all drugs, the decrease in effect size ranging from
10% and 11% for fluoxetine and paroxetine CR to 39% and 41%
for mirtazapine and nefazodone (Table 1). Visual inspection of
funnel plots of published data did not reveal any asymmetry in any
of the 12 comparisons of each drug and placebo (Supporting
Information, Figure S1).
Impact of reporting bias
Figure 2 shows the scatter plot of the pair-wise effect sizes for the
66 possible pair-wise comparisons of antidepressant agents from
the NMA of the 51 published trials against those from the NMA of
the 74 FDA-registered trials. The estimates differed in absolute
value by at least 100% for 30 of 66 pair-wise comparisons (45%)
and by at least 50% for 44 (67%). The median relative difference
between pair-wise effect sizes from the 2 NMAs was 86.1% (25%–
75% percentile 41.4%–203.8%). We found 18 pair-wise effect
sizes of moderate magnitude (0.2–0.5) with published data but
only 3 with FDA data. Agent B was superior to agent A in the
NMA of the 51 published trials and A was superior to B in the
NMA of the 74 FDA-registered trials in 13 comparisons (20%).
Statistical significance was reached for 9 pair-wise comparisons in
the NMA of the 51 published trials and for only 2 pair-wise
comparisons in the NMA of the 74 FDA-registered trials. For
detailed results, see Supporting Information, Table S1.
Figure 3 summarizes the probabilities of being the best
antidepressant. These probabilities varied according to the
published or FDA dataset used: 30.2% or 7.3% for mirtazapine,
41.0% or 33.9% for paroxetine, 0.2% or 8.7% for paroxetine CR,
7.7% or 19.3% for venlafaxine, 14.9% or 25.7% for venlafaxine
XR. They ranged from 0% to 3.0% for the other agents
depending on the dataset used. Moreover, the top 3 agents
differed by dataset used. In the NMA of the 51 published trials,
paroxetine and mirtazapine tied for first place and venlafaxine XR
and venlafaxine tied for third; in the NMA of the 74 FDA-
registered trials, paroxetine was first, and venlafaxine and
venlafaxine XR tied for second. Paroxetine ranked first in both
analyses, and mirtazapine was pushed substantially up in the
ranking in the NMA of published trials. For complementary
graphical summaries, including a rankogram and the Surface
Under the Cumulative Ranking line for each treatment, see
Supporting Information, Figure S2, S3, S4 and S5.
Impact of reporting bias affecting only one drug
Figure 4 shows the results of the NMA assuming that reporting
bias affected a single drug (ie, using published trials with published
effect sizes for this drug and FDA-registered trials for all the 11
other drugs). For instance, for mirtazapine, we used the effect sizes
from 6 trial publications for this drug (out of 10 FDA-registered
trials) and the effect sizes from 64 FDA-registered trials for the
other 11 agents, which resulted in data for an incomplete network
of 70 trials. The probability of mirtazapine ranking first was 80.6%
with analysis of the incomplete network but 7.3% with the 74
FDA-registered trials.
Figure 1. Star-shaped networks of comparisons of data from 74 US Food and Drug Administration (FDA)-registered trials of 12
antidepressants and their 51 related publications. The central node represents the placebo, and each leaf node represents an antidepressant
agent. Each node diameter is proportional to the number of patients who received the antidepressant agent; each connecting line width is
proportional to the number of trials that addressed the comparison.
doi:10.1371/journal.pone.0035219.g001
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FDA data Published data Unpublished FDA data
Drug N SMD (95%CI) T
2 N SMD (95%CI) T
2 N SMD (95%CI) T
2
Bupropion 3 0.17 [0.04; 0.31] 0.00 1 0.27 [0.01; 0.53] NA 2 0.14 [20.02; 0.30] NA
Citalopram 5 0.25 [0.10; 0.38] 0.00 4 0.30 [0.16; 0.44] 0.00 1 0.01 [20.28; 0.30] NA
Duloxetine 8 0.30 [0.21; 0.40] 0.00 6 0.40 [0.29; 0.51] 0.00 2 0.15 [20.05; 0.35] NA
Escitalopram 4 0.31 [0.18; 0.44] 0.00 3 0.36 [0.23; 0.48] 0.00 1 0.15 [20.10; 0.39] NA
Fluoxetine 5 0.26 [0.06; 0.45] 0.02 5 0.29 [0.01; 0.49] 0.02 0 - -
Mirtazapine 10 0.35 [0.17; 0.54] 0.04 6 0.57 [0.39; 0.75] 0.00 4 0.19 [20.17; 0.56] 0.09
Nefazodone 6 0.26 [0.12; 0.40] 0.00 4 0.44 [0.26; 0.61] 0.00 2 0.09 [20.17; 0.34] 0.00
Paroxetine 16 0.42 [0.30; 0.54] 0.00 10 0.59 [0.44; 0.74] 0.00 6 0.20 [20.00; 0.39] 0.00
Paroxetine CR 3 0.32 [0.15; 0.49] 0.00 3 0.36 [0.20; 0.51] 0.00 0 - -
Sertraline 5 0.26 [0.12; 0.39] 0.00 2 0.42 [0.24; 0.60] 0.00 3 0.18 [20.05; 0.40] 0.00
Venlafaxine 6 0.40 [0.24; 0.55] 0.01 5 0.51 [0.36; 0.65] 0.00 1 0.11 [20.21; 0.44] NA
Venlafaxine XR 3 0.40 [0.18; 0.62] 0.02 2 0.51 [0.30; 0.71] 0.00 1 0.19 [20.08; 0.46] NA
Weighted mean effect-size values for each drug were derived using a random-effects model with the method of DerSimonian and Laird. N: number of trials;S M D
(95%CI): summary standardized mean difference of drug vs. placebo derived from random effects meta-analysis (95% confidence interval); T
2 (SE): between-trial
variance as a measure of heterogeneity in meta-analysis (standard error); NA: not assessable.
doi:10.1371/journal.pone.0035219.t001
Figure 2. Scatterplot of estimates of relative efficacy for 66
pair-wise comparisons of the 12 antidepressant agents with
one another derived from network meta-analyses of data from
74 FDA-registered trials and their 51 trial publications. Data are
effect sizes. Positive effect sizes indicate that drug A has higher efficacy
than drug B. The two areas above the uppermost dotted line (labeled
+100%) and below the lowest dotted line (labeled 2100%) correspond
to cases in which an effect size derived from the network meta-analysis
of the 51 published trials differed in absolute value from that derived
from the network meta-analysis of the 74 FDA-registered trials by at
least 100%. The two areas between the 2 upper dotted lines (labeled
+50%) and between the 2 lower dotted lines (labeled 250%)
correspond to cases in which an effect size derived from the network
meta-analysis of the 51 published trials differed in absolute value from
that derived from the network meta-analysis of the 74 FDA-registered
trials by at least 50%. Red-colored points refer to cases in which agent B
was superior to agent A by one network meta-analysis and A was
superior to B by the other network meta-analysis.
doi:10.1371/journal.pone.0035219.g002
Figure 3. Probabilities that each antidepressant drug is the
best according to network meta-analyses of data from 74 FDA-
registered trials or 51 published trials with published effect
sizes. For instance, for mirtazapine, the probability of being the best
was 7.3% and 30.2% according to network-meta-analysis of the 74 FDA-
registered trials and 51 published trials with published effect sizes,
respectively. Drugs for which the probability of being the best was
,5% for both published and FDA data are not labeled (blue area).
doi:10.1371/journal.pone.0035219.g003
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bias, this drug was in most cases strongly favored. The increase in
probability of being the best obtained from the NMA of the
incomplete FDA network rather than that of the 74 FDA-
registered trials varied from 0.7 to 73.3 percentage points. The
agent affected by reporting bias ranked first in 5 of the 12 NMAs
but second (n=2), fourth (n=1) or eighth (n=2) in the NMA of
the whole network of 74 FDA-registered trials. In addition, the
ranking of other drugs could be modified. In 6 of the 12 NMAs,
the top 3 agents differed from those in the NMA of the FDA data,
whereas only small modifications to drug rankings occurred in 5 of
the 12 NMAs.
Impact of publication bias and selective analysis
reporting bias
For publication bias, effect sizes obtained from the NMA of the
51 published trials with FDA effect sizes and the NMA of the 74
FDA-registered trials differed by at least 100% in 19 of 66
comparisons (29%) and by at least 50% in 36 (55%). The median
relative difference between pair-wise effect sizes from these 2
NMAs was 60.6% (25%–75% percentile 28.5%–103.3%).
Similarly, for selective analysis reporting bias, effect sizes
obtained from the NMA of the 51 published trials with published
effect sizes and the NMA of the 51 published trials but with FDA
effect sizes differed by at least 100% in 21 of 66 comparisons (32%)
and by at least 50% in 35 (53%). The median relative difference
between pair-wise effect sizes from these 2 NMAs was 56.2%
(25%–75% percentile 16.3%–135.7%).
Discussion
In this study, we assessed the impact of reporting bias on the
results of NMAs, using as an example FDA-registered placebo-
controlled trials of antidepressants and their matching publica-
tions. First, we found substantial differences in the estimates of the
relative efficacy of competing antidepressants derived from the
NMAs of FDA and published data. For about half the pair-wise
drug comparisons, effect sizes from the NMA of published data
differed, in absolute value, by at least 100% from that from the
NMA of FDA data. The rank-order of efficacy was also affected,
with differences in the probability of being the best agent. Second,
reporting bias affecting only one drug may affect the ranking of all
drugs. Third, publication bias and selective-analysis reporting bias
both contribute to these results.
Our research, based on FDA-registered trials of antidepressants
and their matching publications, aimed not to compare antide-
pressant agents against each other but, rather, to assess the impact
of reporting bias in NMA. We used the dataset already described
and published previously by Turner et al. [19] because to our
knowledge it is the only one available offering the opportunity to
evaluate the impact of reporting bias on NMA. Other studies
compared FDA and published data but they did not cover all
Figure 4. Probabilities of being the best among competing antidepressant agents when reporting bias affects one specific agent.
The first stacked bar at the left corresponds to the network meta-analysis free of reporting biases (ie, with the data from the 74 FDA-registered trials).
The other stacked bars correspond to the 12 network meta-analyses in which reporting bias hypothetically affects one specific agent in turn. For
instance, for mirtazapine, we used the 6 published trials (out of 10 FDA-registered trials), with published effect sizes, and data from the 64 FDA-
registered trials for the other 11 agents, which resulted in an incomplete FDA network of 70 trials; the probability of mirtazapine being the best was
80.6% with data from the incomplete FDA network and 7.3% with data from the 74 FDA-registered trials. For the sake of clarity, we presented in each
analysis the 3 drugs with the 3 highest probabilities of being the best among competing antidepressant agents. Bup: Bupropion; Cit: Citalopram; Dul :
Duloxetine ; Esc: Escitalopram; Flu: Fluoxetine; Mir: Mirtazapine ; Nef: Nefazodone ; Par: Paroxetine; Par CR: Paroxetine CR; Ser: Sertraline; Ven:
Venlafaxine; VenXR: Venlafaxine XR.
doi:10.1371/journal.pone.0035219.g004
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performing NMA [28,29].
Our study adds 3 important pieces of new information. First,
our analysis concerned NMAs. An extensive literature has shown
the existence and impact of reporting bias in conventional meta-
analysis, including the very study of Turner et al. [19]. However,
this issue remains poorly explored in the indirect-comparison or
NMA framework. In particular, most existing NMAs fail to
address or even discuss potential reporting bias. In this case study,
we showed that NMA led to highly misleading estimates of the
efficacy of competing interventions in the presence of reporting
bias. With evidence of reporting bias in any conventional pair-wise
meta-analyses in the network, the results of NMA should be
interpreted with great caution. The recognition of this issue is even
more important considering the lack of a recognized method to
identify and deal with reporting bias in the NMA framework.
Funnel plots and tests for asymmetry could be applied to each
pair-wise comparison in the network. However, the number of
trials addressing each pair-wise comparison may often be limited,
which would prevent this approach from documenting or
excluding reporting bias appropriately [30,31]. Each of our 12
comparisons between drugs and placebo were represented by no
more than 10 trial publications, so applying asymmetry tests would
be inappropriate or not meaningful [32]. Moreover, even with full
knowledge of the existence of unpublished FDA-registered trials,
the visual assessment of funnel plots did not reveal any asymmetry.
Plots with reporting bias had approximately symmetric appear-
ance (Supporting Information, Figure S1). In some contexts, one
could assume that reporting biases affect the different drugs
similarly and assume exchangeability of the trial selection
processes across drugs; methods that ‘‘borrow strength’’ from all
trials in the network could be applied, as was performed recently
for the case study we considered [30,33]. As well, in specific
situations, a strong publication bias is probably not necessary to
influence the results. For instance, reporting bias affecting
venlafaxine trials related to only 1 trial with unpublished results
among 6 trials; when hypothetical reporting bias affected
venlafaxine only, venlafaxine ranked first.
Second, we also showed that reporting bias operates differently
in NMA and in usual meta-analysis. The major difference is that
in usual meta-analysis, reporting bias affects only the results of the
drug of interest. In contrast, in NMA, reporting bias affecting one
of a number of drugs could affect the ranking of all drugs (ie, ‘‘one
bad apple could spoil the barrel’’). In the presence of reporting
bias, results from NMA can be valid only if findings of
independently conducted research are made equally available.
Third, publication bias and selective analysis reporting bias both
affected the estimates of treatment efficacy. The impact of
reporting bias in NMA is not the algebraic sum of the impact of
the two biases. The substantial impact of selective analysis
reporting bias is of major practical importance. In fact, contrary
to publication bias, selective analysis reporting bias is less likely to
be improved by trial registration only, and an additional
independent statistical analysis with access to the complete raw
data set, the trial protocol and the pre-specified analysis plan may
be required to ensure integrity [34,35]. NMAs and conventional
meta-analyses both should include FDA reviews of approved drug
products, which are now publicly available from the Center for
Drug Evaluation and Research website, in searches for published
and unpublished results [27,36].
Our study might have several limitations. First, this empirical
analysis relied on a particular network dedicated to a specific
clinical condition (major depression), one class of drugs (antide-
pressant drugs) and one type of trial (placebo-controlled trials).
This specificity might limit the generalizability of our findings. In
this case study, reporting bias led to overestimation of effect sizes
for all drugs. However, a reanalysis of meta-analyses with the
addition of unpublished data from the FDA for 6 other drug
classes has shown that the effect of including unpublished FDA
data varies by drug and outcome, with the possibility of a decrease
but also an increase in estimates of efficacy [18]. The network of
evidence from the Turner et al. dataset was limited to placebo-
controlled trials, resulting in a radiating star shape. However, it
corresponds to geometry of real-world networks, since simple
networks of 3 different interventions without direct head-to-head
trials are frequent (60% of identified indirect comparisons in a
recent review [37]) and, in cases of three or more interventions,
examples of networks with star or ladder designs (containing no
loop) have been reported frequently [38,39]. Turner’s network of
evidence did not include the existing head-to-head trials [40,41].
Unfortunately, we do not have access to the potential unpublished
results from head-to-head trials. Regulatory registration is
uncommon for head-to-head trials and if industry-furnished data
were available they may still suffer from selective analysis bias.
Therefore, we could not perform an unbiased complete NMA
(including all placebo-controlled and head-to-head trials). How-
ever, the addition of published and unpublished head-to-head
trials in our analysis may modify the estimated impact of reporting
bias. Extrapolating our results to a network with both direct and
indirect evidence is not straightforward. The direction of bias in
estimating treatment effect because of reporting bias is uncertain
in head-to-head trials: the sponsored treatment could be favored
[5,42] or the newest treatment could be favored [43,44] and
disentangling the sources of bias operating on direct and indirect
evidence would be difficult. Second, the choice of the FDA-
registered trials as a reference standard could be debated but
seems reasonable. Pair-wise effect sizes derived from FDA data
should not be considered unbiased estimates of antidepressants
efficacy per se but may be considered unbiased estimates of
treatment effects via NMAs of placebo-controlled trials. In fact,
during the application review process for new drugs, the FDA re-
analyses the trial data using raw data from the sponsor in
adherence to the pre-specified statistical methods in the trial
protocols [45]. This FDA dataset was previously described as ‘‘an
unbiased (but not the complete) body of evidence’’ [30].
Moreover, as usual, checking the required assumptions for the
indirect treatment comparisons framework is difficult. However,
there is no reason to suggest that these conditions are not met.
Homogeneity was satisfied in our analysis. Trial similarity is likely
because all trials were randomized, double-blind, placebo-
controlled studies of drugs for the short-term treatment of
depression, with close selection criteria. Other NMAs have been
performed in this field and did not raise concerns about these
assumptions [40,41]. In addition, if one of these assumptions were
not met, our analysis would not likely have been affected because it
probably would have concerned both NMAs of published and
FDA data that we compared. An additional required assumption
for NMA is exchangeability, which implies that if all the RCTs
had included all the treatments evaluated in the network, then
each trial would have estimated the same pair wise effect sizes. The
consistency assumption strictly follows from the exchangeability
assumption. Star-networks do not allow for quantifying the
amount of incoherence between indirect and direct evidence.
Unequal availability of trials for different comparisons, because of
reporting bias, may result in inconsistency (ie, differential reporting
bias may lead to the violation of this assumption) [46]. When
reporting bias hypothetically affected only one drug, we basically
assessed the consequences of violating the assumption of
Impact of Reporting Bias in Network Meta-Analyses
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35219exchangeability and found that the ranking of all drugs could be
modified. Differential reporting bias could occur across and within
competing interventions. For instance, reporting bias may differ
between trials conducted before and after the FDA Amendments
Act of 2007, which expanded the legal requirements for trial
reporting [47].
NMA is a promising statistical tool, especially for comparative
effectiveness research, but authors should be aware of the potential
impact of reporting bias on the results of such analysis. NMA
validity is conditioned upon the equal availability of findings of
independently conducted research. Authors should interpret the
results with great caution when reporting bias is detected in any
pair-wise comparison and should be aware that reporting bias is
likely not detected nor excluded appropriately in the NMA
framework as well.
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